Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2013Global Markets DirectMarch 18, 2013 534 Pages - SKU: GMD4999230 |
Additional Information
Report Excerpt
Coverage
The objective of updating Global Markets Direct coverage is to ensure that it represents the most up to date vision of the industry possible. Changes the industry taxonomy are built on the basis of extensive research of company, association and competitor sources.Company coverage is based on three key factors: market capitalization, revenues and media attention/innovation/ market potential.An exhaustive search of 56 member exchanges is conducted and companies are prioritized on the basis of their market capitalization.The estimated revenues of all major companies, including private and governmental, are gathered and used to prioritize coverage.Companies which are making the news, or which are of particular interest due to their innovative approach are prioritized.Global Markets Direct aims to cover all major news events and deals in the pharmaceutical industry, updated on a daily basis.The coverage is further streamlined and strengthened with additional inputs from Global Markets Direct Expert Panel (see below).
Secondary Research
The research process begins with exhaustive secondary research on internal and external sources being carried out to source qualitative and quantitative information relating to each market.The secondary research sources that are typically referred to include, but are not limited to:Company websites, annual reports, financial reports, broker reports, investor presentations and SEC FilingsIndustry trade journals and other literatureInternal and external proprietary databasesNational government documents, statistical databases and market reportsNews articles, press releases and web-casts specific to the companies operating in the market.
More Respiratory/Pulmonary reports by Global Markets Direct
Pulmonary Tuberculosis – Pipeline Review, H1 2013 by Global Markets Direct
Pulmonary Tuberculosis – Pipeline Review, H1 2013SummaryGlobal Markets Direct’s, 'Pulmonary Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This ...
Pulmonary Arterial Hypertension – Pipeline Review, H1 2013 by Global Markets Direct
Pulmonary Arterial Hypertension – Pipeline Review, H1 2013SummaryGlobal Markets Direct’s, 'Pulmonary Arterial Hypertension - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic ...
Cystic Fibrosis – Pipeline Review, H1 2013 by Global Markets Direct
Cystic Fibrosis – Pipeline Review, H1 2013SummaryGlobal Markets Direct’s, 'Cystic Fibrosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This ...
Lung Cancer – Pipeline Review, H1 2013 by Global Markets Direct
See all reports like this >>Lung Cancer – Pipeline Review, H1 2013SummaryGlobal Markets Direct’s, 'Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This ...
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Respiratory/Pulmonary Reports
- Pneumonia Treatment Drugs Markets in China
- OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017
- Pulmonary Tuberculosis – Pipeline Review, H1 2013
- Analytical Tool - Lung Cancer
